Elucidating the Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Intolerance in People With Cystic Fibrosis

Affiliations

¹ Cystic Fibrosis Centre Copenhagen, Department of Infectious Diseases, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark.
² Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne NE1 7RU, UK.

Editorial

Bibi Uhre Nielsen et al. J Clin Endocrinol Metab. 2025.

. 2025 Mar 24:dgaf165.

doi: 10.1210/clinem/dgaf165. Online ahead of print.

¹ Cystic Fibrosis Centre Copenhagen, Department of Infectious Diseases, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark.
² Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne NE1 7RU, UK.

No abstract available

Keywords: cystic fibrosis; cystic fibrosis-related diabetes; elexacaftor/tezacaftor/ivacaftor; insulin secretion; insulin sensitivity.

Comment on

Glycemia and Insulin Secretion in Cystic Fibrosis 2 Years After Elexacaftor/Tezacaftor/Ivacaftor: PROMISE-ENDO.
Chan CL, Shirley Bezerra M, Stefanovski D, Gallop RJ, Walega R, Donaldson SH, Frederick CA, Freedman SD, Gelfond D, Hoffman LR, Narkewicz MR, Rowe SM, Sagel SD, Schwarzenberg SJ, Solomon GM, Stalvey MS, Kelly A. Chan CL, et al. J Clin Endocrinol Metab. 2025 Aug 7;110(9):2674-2684. doi: 10.1210/clinem/dgae857. J Clin Endocrinol Metab. 2025. PMID: 39657947